Literature DB >> 21289148

Detection of rapidly growing mycobacteria in routine cultures of samples from patients with cystic fibrosis.

Charles R Esther1, Steven Hoberman, Jason Fine, Sonia Allen, Karissa Culbreath, Kyle Rodino, Alan Kerr, Peter Gilligan.   

Abstract

Rapidly growing mycobacteria (RGM) are respiratory pathogens in patients with cystic fibrosis (CF), but detection generally requires specialized cultures for acid-fast bacilli (AFB; AFB cultures). We determined that RGM could be recovered from routine cultures of samples from patients with CF by extending incubation of the Burkholderia cepacia selective agar (BCSA) from 5 to 14 days. To explore the impact of this modification, we compared results from routine and AFB cultures of samples from CF patients for 2 years before (4,212 samples by routine culture, 1,810 samples by AFB culture, 670 patients) and 2 years after (4,720 samples by routine culture, 2,179 samples by AFB culture, 695 patients) the change. Clinical relevance was assessed with samples from a subgroup of 340 patients followed regularly throughout both periods. Extending incubation of BCSA enhanced RGM recovery from routine cultures (0.7% before, 2.8% after; P < 0.001); recovery from AFB cultures was unchanged (5.5% before, 5.7% after). Estimates of RGM detection sensitivity by culture or patient-based methods ranged from ∼65 to 75% for routine cultures (nonsignificantly lower than the ∼80 to 85% for AFB cultures) and were adversely affected by coculture with mold or nonpseudomonal, nonfermenting Gram-negative rods. In the after period, 16 CF patients met the criteria for RGM infection by routine culture, including 4 who did not meet the criteria for RGM infection by AFB culture. We conclude that a simple methodological change enhanced recovery of RGM from routine cultures. The modified culture method could be utilized to improve screening for RGM in CF patients or as a simpler method to follow patients with known RGM infection. However, this method should be used cautiously in patients with certain coinfections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289148      PMCID: PMC3122866          DOI: 10.1128/JCM.02379-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Value of the chlorhexidine decontamination method for recovery of nontuberculous mycobacteria from sputum samples of patients with cystic fibrosis.

Authors:  Agnès Ferroni; Hoang Vu-Thien; Philippe Lanotte; Muriel Le Bourgeois; Isabelle Sermet-Gaudelus; Brigitte Fauroux; Sophie Marchand; Françoise Varaigne; Patrick Berche; Jean-Louis Gaillard; Catherine Offredo
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group.

Authors:  S Whittier; K Olivier; P Gilligan; M Knowles; P Della-Latta
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

3.  Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease.

Authors:  Kenneth N Olivier; David J Weber; Ji-Hyun Lee; Allison Handler; Gail Tudor; Paul L Molina; Joseph Tomashefski; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2002-11-14       Impact factor: 21.405

4.  Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

Authors:  Kenneth N Olivier; David J Weber; Richard J Wallace; Ali R Faiz; Ji-Hyun Lee; Yansheng Zhang; Barbara A Brown-Elliot; Allison Handler; Rebecca W Wilson; Michael S Schechter; Lloyd J Edwards; Subha Chakraborti; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2002-11-14       Impact factor: 21.405

Review 5.  Pulmonary disease caused by rapidly growing mycobacteria.

Authors:  Charles L Daley; David E Griffith
Journal:  Clin Chest Med       Date:  2002-09       Impact factor: 2.878

6.  Nontuberculous mycobacterial infection in young children with cystic fibrosis.

Authors:  Charles R Esther; Marianna M Henry; Paul L Molina; Margaret W Leigh
Journal:  Pediatr Pulmonol       Date:  2005-07

7.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors:  Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

8.  Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis.

Authors:  Charles R Esther; Denise A Esserman; Peter Gilligan; Alan Kerr; Peadar G Noone
Journal:  J Cyst Fibros       Date:  2010-01-13       Impact factor: 5.482

Review 9.  Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Infect Control Hosp Epidemiol       Date:  2003-05       Impact factor: 3.254

Review 10.  The natural history of nontuberculous mycobacteria in patients with cystic fibrosis.

Authors:  Kenneth N Olivier
Journal:  Paediatr Respir Rev       Date:  2004       Impact factor: 2.726

View more
  10 in total

1.  Evaluation of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Samples from Patients with Cystic Fibrosis in the United States.

Authors:  Rongpong Plongla; Clair L Preece; John D Perry; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2017-02-22       Impact factor: 5.948

2.  Evaluation of Various Culture Media for Detection of Rapidly Growing Mycobacteria from Patients with Cystic Fibrosis.

Authors:  Clair L Preece; Thomas A Wichelhaus; Audrey Perry; Amanda L Jones; Stephen P Cummings; John D Perry; Michael Hogardt
Journal:  J Clin Microbiol       Date:  2016-04-20       Impact factor: 5.948

Review 3.  Practice Guidelines for Clinical Microbiology Laboratories: Mycobacteria.

Authors:  Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson
Journal:  Clin Microbiol Rev       Date:  2018-01-31       Impact factor: 26.132

4.  Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis.

Authors:  Ian Eltringham; Julie Pickering; Helen Gough; Clair L Preece; John D Perry
Journal:  J Clin Microbiol       Date:  2016-05-25       Impact factor: 5.948

5.  Mycobacterium abscessus Complex Identification with Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.

Authors:  Theofano Panagea; David H Pincus; Dorothy Grogono; Melissa Jones; Josephine Bryant; Julian Parkhill; R Andres Floto; Peter Gilligan
Journal:  J Clin Microbiol       Date:  2015-05-06       Impact factor: 5.948

Review 6.  Infections in patients with cystic fibrosis: diagnostic microbiology update.

Authors:  Peter H Gilligan
Journal:  Clin Lab Med       Date:  2014-04-12       Impact factor: 1.935

7.  Evaluation of a novel rapidly-growing mycobacteria medium for isolation of Mycobacterium abscessus complex from respiratory specimens from patients with bronchiectasis.

Authors:  Barbara A Brown-Elliott; Susan Molina; Travis Fly; Ousman Njie; Patricia Stribley; Dominic Stephenson; Richard J Wallace; John D Perry
Journal:  Heliyon       Date:  2019-10-24

8.  Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia.

Authors:  Tavs Qvist; Marita Gilljam; Bodil Jönsson; David Taylor-Robinson; Søren Jensen-Fangel; Mikala Wang; Anita Svahn; Karsten Kötz; Lennart Hansson; Annika Hollsing; Christine R Hansen; Pål L Finstad; Tania Pressler; Niels Høiby; Terese L Katzenstein
Journal:  J Cyst Fibros       Date:  2014-08-30       Impact factor: 5.482

9.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139

10.  Mycobacterium abscessus - an uncommon, but important cause of peritoneal dialysis-associated peritonitis - case report and literature review.

Authors:  Anup Singh Jheeta; Jayakeerthi Rangaiah; John Clark; David Makanjuola; Subash Somalanka
Journal:  BMC Nephrol       Date:  2020-11-17       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.